BR9405843A - Processo para reduzir perda óssea e uso de um composto - Google Patents

Processo para reduzir perda óssea e uso de um composto

Info

Publication number
BR9405843A
BR9405843A BR9405843A BR9405843A BR9405843A BR 9405843 A BR9405843 A BR 9405843A BR 9405843 A BR9405843 A BR 9405843A BR 9405843 A BR9405843 A BR 9405843A BR 9405843 A BR9405843 A BR 9405843A
Authority
BR
Brazil
Prior art keywords
bone loss
compound
phenyl
reduce bone
diarylchromans
Prior art date
Application number
BR9405843A
Other languages
English (en)
Inventor
Virender M Labroo
James R Piggott
Steven D Bain
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of BR9405843A publication Critical patent/BR9405843A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Prostheses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pens And Brushes (AREA)
  • Confectionery (AREA)
BR9405843A 1993-03-11 1994-01-13 Processo para reduzir perda óssea e uso de um composto BR9405843A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/029,729 US5280040A (en) 1993-03-11 1993-03-11 Methods for reducing bone loss using centchroman derivatives
PCT/US1994/000633 WO1994020098A1 (en) 1993-03-11 1994-01-13 Methods for inhibiting bone loss with 3,4-diarylchroman

Publications (1)

Publication Number Publication Date
BR9405843A true BR9405843A (pt) 1996-01-16

Family

ID=21850559

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9405843A BR9405843A (pt) 1993-03-11 1994-01-13 Processo para reduzir perda óssea e uso de um composto

Country Status (19)

Country Link
US (2) US5280040A (pt)
EP (1) EP0688214B1 (pt)
JP (1) JP2834581B2 (pt)
KR (1) KR100263009B1 (pt)
AT (1) ATE178488T1 (pt)
AU (2) AU674394B2 (pt)
BR (1) BR9405843A (pt)
CA (1) CA2157879C (pt)
CZ (1) CZ287603B6 (pt)
DE (1) DE69417733T2 (pt)
DK (1) DK0688214T3 (pt)
ES (1) ES2131678T3 (pt)
GR (1) GR3030128T3 (pt)
HU (1) HUT74575A (pt)
NO (1) NO309361B1 (pt)
NZ (1) NZ262569A (pt)
RU (1) RU2166940C2 (pt)
SG (1) SG65584A1 (pt)
WO (1) WO1994020098A1 (pt)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) * 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
US5389646A (en) * 1993-12-30 1995-02-14 Zymogenetics, Inc. Methods for treatment and prevention of bone loss using 2,3-benzopyrans
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
US5637598A (en) * 1994-11-18 1997-06-10 Eli Lilly And Company Methods of inhibiting bone loss
AU702407B2 (en) * 1995-01-13 1999-02-18 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment of prophylaxis of idiopathic or physiologic gynaecomastia
CZ211897A3 (en) * 1995-01-20 1997-12-17 Novo Nordisk As Use of 3,4-diphenylchromans for preparing pharmaceutical preparations used for dilation of vessels
TW448046B (en) * 1995-01-20 2001-08-01 Novo Nordisk As Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity
EP0809495A1 (en) * 1995-01-20 1997-12-03 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of cerebral degenerative disorders
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US6008208A (en) 1995-10-23 1999-12-28 Osteoscreen, Inc. Compositions and methods for treating bone deficit conditions
JP2000513324A (ja) * 1995-10-23 2000-10-10 ザイモジェネティクス，インコーポレイテッド 骨欠損状態を処置するための組成物および方法
US5883118A (en) * 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
US5859045A (en) * 1996-05-08 1999-01-12 Novo Nordisk A/S Novo Alle Crystalline -! 3R 4R-trans-7 methoxy 2,2-dimethyl1-3-phenyl 1-4 4-12 pyrrolidin-1 -Y1!ethoxyl 1!chromane hydrogen fumarate
EP0912543B1 (en) * 1996-05-08 2004-03-24 Novo Nordisk A/S Crystalline (-)-3r,4r-trans-7-methoxy-2,2-dimethyl-3-phenyl-4-[4- 2-(pyrrolidin-1-yl)ethoxy]phenyl chromane, hydrogen fumarate
US5756539A (en) * 1996-07-11 1998-05-26 Novo Nordis A/S 3, 4-diphenyl chromans for inhibiting one or more psychiatric disorders
US5780502A (en) * 1996-07-12 1998-07-14 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more symptoms of premenstrual syndrome
US5922753A (en) * 1996-10-23 1999-07-13 Zymogenetics, Inc. Methods for treating bone deficit conditions with benzothiazole
US5965573A (en) * 1996-10-23 1999-10-12 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
AU4988997A (en) * 1996-10-23 1998-05-15 Osteoscreen, Inc. Compositions and methods for treating bone deficit conditions
US6251901B1 (en) 1996-10-23 2001-06-26 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US6017940A (en) * 1996-10-23 2000-01-25 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US5939444A (en) * 1996-10-23 1999-08-17 Zymogenetic, Inc. Compositions and methods for treating bone deficit conditions
US5990169A (en) * 1996-10-23 1999-11-23 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US5919808A (en) * 1996-10-23 1999-07-06 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US5948776A (en) * 1996-10-23 1999-09-07 Zymogenetic, Inc. Compositions and methods for treating bone deficit conditions
US6153631A (en) * 1996-10-23 2000-11-28 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US6342514B1 (en) 1996-10-23 2002-01-29 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US6043269A (en) * 1996-10-28 2000-03-28 Novo Nordisk A/S cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
WO1998018772A1 (en) * 1996-10-28 1998-05-07 Novo Nordisk A/S NOVEL cis-3,4-CHROMAN DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES
US5994390A (en) * 1996-10-28 1999-11-30 Novo Nordisk Trans-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
EP0937059A1 (en) * 1996-10-28 1999-08-25 Novo Nordisk A/S NOVEL $i(TRANS)-3,4-CHROMAN DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES
US6316494B1 (en) 1996-10-28 2001-11-13 Novo Nordisk A/S cis3, 4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
US5958967A (en) * 1996-10-28 1999-09-28 Novo Nordisk A/S Cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
AU4700097A (en) * 1996-10-28 1998-05-22 Novo Nordisk A/S Novel (cis)-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
DE69717843T2 (de) * 1996-10-28 2003-09-25 Novo Nordisk A/S, Bagsvaerd Cis-3,4-chromanderivate zur vorbeugung oder behandlungvon oestrogenbezogenen krankheiten oder syndromen
ZA979644B (en) * 1996-10-28 1998-04-28 Novo Nordisk As Heterocyclic compounds, compositions and uses.
JP2001502704A (ja) * 1996-10-28 2001-02-27 ノボ ノルディスク アクティーゼルスカブ エストロゲン関連疾患又は症候群の予防又は処置において有用な新規ｃｉｓ―３，４―クロマン誘導体の新規の（―）―鏡像異性体
CA2270056A1 (en) * 1996-10-28 1998-05-07 Poul Jacobsen Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
ATE229519T1 (de) * 1996-10-28 2002-12-15 Novo Nordisk As Neue cis-3,4-chromanderivate zur vorbeugung oder behandlung von oestrogenbezogenen krankheiten oder syndromen
ZA979648B (en) * 1996-10-28 1998-04-28 Novo Nordisk As Heterocyclic compounds, compositions and uses.
US5985306A (en) * 1996-10-28 1999-11-16 Novo Nordisk A/S (+)-enantiomers of cis-3,4-chroman derivatives useful in prevention or treatment of estrogen diseases or syndromes
US5919817A (en) * 1996-10-28 1999-07-06 Novo Nordisk A/S Cis-3, 4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
US5977158A (en) * 1996-11-28 1999-11-02 Novo Nordisk A/S Pharmaceutical formulations comprising levormeloxifene compounds
WO1998023270A1 (en) * 1996-11-28 1998-06-04 Novo Nordisk A/S Pharmaceutical formulation
US6376476B1 (en) * 1996-12-13 2002-04-23 Zymogenetics Corporation Isoprenoid pathway inhibitors for stimulating bone growth
US6080779A (en) * 1996-12-13 2000-06-27 Osteoscreen, Inc. Compositions and methods for stimulating bone growth
EP0944312B9 (en) * 1996-12-13 2006-07-05 ZymoGenetics, Inc. Compositions and methods for stimulating bone growth
ATE222103T1 (de) * 1997-02-27 2002-08-15 Novo Nordisk As Inklusionskomplexe in waessriger loesung
AU6959898A (en) 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
US6372776B2 (en) * 1997-06-12 2002-04-16 Novo Nordisk A/S Crystalline(−)-3R,4R-trans-7-methoxy-2,2-dimethyl-3-phenyl-4-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}chromane, hydrogen maleate
US6649631B1 (en) 1997-10-23 2003-11-18 The Board Of Regents Of The University Of Texas System Compositions and methods for treating bone deficit conditions
ZA989763B (en) * 1997-11-07 1999-05-07 Novo Nordisk As Pharmaceutical composition comprising levormeloxifene in low dose
WO1999024032A1 (en) * 1997-11-10 1999-05-20 Novo Nordisk A/S Transdermal delivery of 3,4-diarylchromans
US6838436B1 (en) 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6902721B1 (en) 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6525084B2 (en) * 1998-07-23 2003-02-25 Novo Nordisk A/S Stable pharmaceutical formulation
JP4896335B2 (ja) 2000-03-01 2012-03-14 ナームローゼ・フエンノートチヤツプ・オルガノン エストロゲン化合物としてのクロマン誘導体
JP4332349B2 (ja) * 2001-01-24 2009-09-16 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ ２ｈ−１−ベンゾピラン誘導体、それらの製造法及びそれらの製薬学的組成物
EP1281710A1 (en) * 2001-08-03 2003-02-05 CHIESI FARMACEUTICI S.p.A. 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
ES2236056T3 (es) * 2001-01-24 2005-07-16 Chiesi Farmaceutici S.P.A. Derivados de 2h-1-benzopirano, procedimientos para su preparacion y composiciones farmaceuticas de los mismos.
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
AU2003205165A1 (en) * 2002-01-14 2003-07-30 Osteoscreen, Inc. Methods and compositions for stimulating bone growth using inhibitors of microtubule assembly
US7288535B2 (en) * 2002-05-02 2007-10-30 Osteoscreen, Inc. Methods and compositions for stimulating bone growth using nitric oxide releasing bisphosphonate conjugates
US7041309B2 (en) * 2002-06-13 2006-05-09 Neuropro Technologies, Inc. Spinal fusion using an HMG-CoA reductase inhibitor
US20040254238A1 (en) * 2003-04-07 2004-12-16 Osteoscreen Bone growth stimulation with NO/statin and other NO modulating combinations
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
ATE532777T1 (de) * 2004-09-21 2011-11-15 Marshall Edwards Inc Substituierte chromanderivate, medikamente und anwendungen in der therapie
US9457056B2 (en) * 2007-12-04 2016-10-04 Ben-Gurion University Of The Negev Research And Development Authority Peptides comprising alternating hydrophobic and anionic amino acids for treatment of osteoporosis
JP6013349B2 (ja) 2010-11-01 2016-10-25 メイ ファーマ, インク.Mei Pharma, Inc. 癌の処置のためのイソフラボノイド化合物および方法
AU2015213484B2 (en) 2014-02-07 2015-11-05 Kazia Therapeutics Limited Functionalised benzopyran compounds and use thereof
ES2877712T3 (es) 2015-02-02 2021-11-17 Mei Pharma Inc Terapias combinadas para su uso en el tratamiento del cáncer de mama
LU100182B1 (en) * 2017-04-06 2018-10-15 Univ Hamburg Eppendorf Uke Therapeutic use of microRNA 19A/19B

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340276A (en) * 1964-04-01 1967-09-05 Ciba Geigy Corp 3, 4-diphenyl-chromans
US3822287A (en) * 1969-04-17 1974-07-02 Rexall Drug Chemical Process for preparation of substituted 3,4-(diphenyl)chromans
US4210644A (en) * 1978-02-23 1980-07-01 The Johns Hopkins University Male contraception
US4447622A (en) * 1981-09-22 1984-05-08 Council Of Scientific And Industrial Research Rafi Marg Preparation of l- and d-isomers of dl-3,4-trans-2,2-disubstituted-3,4-diarylchromans and derivatives thereof
US4489056A (en) * 1982-06-30 1984-12-18 Merck & Co., Inc. Acid anhydrides as rate controlling agent for the erosion of polymers which latter polymers have beneficial substances dispersed throughout their matrix or where the polymer matrix surrounds the beneficial substance
JPS6054379A (ja) * 1983-09-05 1985-03-28 Takeda Chem Ind Ltd 新規４ｈ−１−ベンゾピラン−４−オン誘導体，その製法および用途
US4644012A (en) * 1983-12-21 1987-02-17 Takeda Chemical Industries, Ltd. Treatment for osteoporosis
US4902679A (en) * 1985-12-13 1990-02-20 Norwich Eaton Pharmaceuticals, Inc. Methods of treating diseases with certain geminal diphosphonates
GB2205240B (en) * 1987-06-03 1991-01-09 Erba Carlo Spa N-imidazolyl derivatives of bicyclic compounds useful in medicine
US5015661A (en) * 1988-08-09 1991-05-14 Hoffmann-La Roche Inc. Chromanes and their pharmaceutical compositions and methods
US5063234A (en) * 1990-05-25 1991-11-05 Eli Lilly And Company Method of inhibiting demineralization of bone
JP3502403B2 (ja) * 1991-12-16 2004-03-02 アベンティス ファーマ株式会社 骨吸収抑制剤
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives

Also Published As

Publication number Publication date
NZ262569A (en) 1997-08-22
AU674394B2 (en) 1996-12-19
CA2157879C (en) 2000-08-29
US5464862A (en) 1995-11-07
ES2131678T3 (es) 1999-08-01
AU1639497A (en) 1997-05-22
JP2834581B2 (ja) 1998-12-09
US5280040A (en) 1994-01-18
AU6230294A (en) 1994-09-26
AU695497B2 (en) 1998-08-13
NO953542L (no) 1995-09-08
CZ287603B6 (en) 2001-01-17
CZ232095A3 (en) 1996-04-17
RU2166940C2 (ru) 2001-05-20
NO309361B1 (no) 2001-01-22
ATE178488T1 (de) 1999-04-15
DK0688214T3 (da) 2000-10-09
KR960700708A (ko) 1996-02-24
GR3030128T3 (en) 1999-07-30
DE69417733T2 (de) 1999-09-16
EP0688214A1 (en) 1995-12-27
EP0688214B1 (en) 1999-04-07
JPH08506346A (ja) 1996-07-09
HUT74575A (en) 1997-01-28
WO1994020098A1 (en) 1994-09-15
SG65584A1 (en) 1999-06-22
KR100263009B1 (ko) 2000-08-01
NO953542D0 (no) 1995-09-08
HU9502624D0 (en) 1995-11-28
CA2157879A1 (en) 1994-09-12
DE69417733D1 (de) 1999-05-12

Similar Documents

Publication Publication Date Title
BR9405843A (pt) Processo para reduzir perda óssea e uso de um composto
SE9504661D0 (sv) New compounds
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
ATE198835T1 (de) Knochenwachstumsfördernde zusammensetzung
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
YU49026B (sh) UPOTREBA 17 Гџ -(N-TERC-BUTILKARBAMOIL)-4-AZA-5-ALFA-ANDROST-1-3-ON ZA PROIZVODNJU LEKA ZA TRETIRANJE ANDROGENE ALOPECIJE
BR0209283A (pt) Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme
ATE193442T1 (de) 3,4-diarylchromane zur behandlung von dermatitis
FI972434A0 (fi) Lamotrigiiniä sisältävä farmaseuttinen koostumus
CA2180178A1 (en) Use of 2,3-diaryl-1-benzopyran derivatives for the manufacture of a medicament in the treatment and prevention of bone loss and osteoporosis
PT100415A (pt) Novas morfolinas de accao farmaceutica, e processo para a sua preparacao
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy
YU242789A (en) New compound, 4-fluoro-2-//(4-metoxy-2-pyridin-yl)methylsulphinyl/-1h-benzimidazole and process for obtaining
SE9504662D0 (sv) New compounds
BR9611276A (pt) Composto formulação farmacêutica processo para tratamento ou profilaxia de doenças ou condições de seres humanos e uso de um composto
BR9508021A (pt) Composição farmacêutica para o tratamento de distúrbios esquizofrênicos, uso de um agente imunossupressor, e, processo de tratamento de um paciente esquizofrênico
ZA935045B (en) Pharmacologically active alfa-(tertiary-aminomethyl)-ben-zenemethanol derivatives
BRPI0415964A (pt) uso de um composto, composto, formulação farmacêutica, e, processo para preparar um composto
ES2131331T3 (es) Uso de benzotiofenos para la preparacion de un medicamento para reducir la formacion de cicatrices en la curacion de heridas.
AR023344A1 (es) 4-ariloxiindoles, una composicion farmaceutica que los contienen y el uso de los mismos para la preparacion de medicamentos

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal
CKFC Appeal: appeal against refusal